Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

This study has been completed.
Information provided by:
Seqirus Identifier:
First received: June 17, 2008
Last updated: July 17, 2016
Last verified: November 2008
The purpose of this study is to determine the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine in a two dose primary vaccination series, with a 12-month booster vaccination, in a paediatric population equal to or greater than 6 months to less than 9 years old.

Condition Intervention Phase
Biological: Influenza Virus Vaccine
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age).

Resource links provided by NLM:

Further study details as provided by Seqirus:

Primary Outcome Measures:
  • Safety of CSL Influenza Virus Vaccine in a Paediatric population through the assessment of the frequency of Local and general solicited symptoms, Unsolicited Adverse Events (UAE),Serious Adverse Events (SAEs) [ Time Frame: Local & general solicited symptoms for 7 days post each vaccination, UAEs for 30 days post each vaccination, SAEs for 6 months after the last primary vaccination and 6 months after the booster vaccination ]

Secondary Outcome Measures:
  • Evaluate immunogenicity response to CSL Influenza Virus Vaccine in Paediatric population according to the criteria of the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines [ Time Frame: 30 days after each vaccine dose ]

Enrollment: 298
Study Start Date: March 2005
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Group A
Equal to or greater 6 months to less than 3 years old
Biological: Influenza Virus Vaccine
2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
Group B
Equal to or greater 3 years to less than 9 years old
Biological: Influenza Virus Vaccine
2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose


Ages Eligible for Study:   6 Months to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Be healthy male or female children, aged = or > 6 months to < 9 years at the time of first study vaccination; Note: = or > 6 refers to 6 calendar months
  2. Parent(s) or Guardian(s) to provide written informed consent to participate in the study;
  3. Be able to provide a pre-vaccination sample of up to 5mL of venous blood without undue distress/discomfort and
  4. Be born after a normal gestation period (between 36 and 42 weeks).

Exclusion Criteria:

  1. Known allergy to eggs, chicken feathers, neomycin, polymyxin, or any components of the vaccine;
  2. Previous influenza vaccination;
  3. Clinical signs of active infection and/or an axillary temperature of = or >37.5 degrees Celsius or oral temperature of = or >38 degrees Celsius at study entry. Study entry may be deferred for such individuals, at the discretion of the Principal Investigator;
  4. Confirmed or suspected immunosuppressive condition (including cancer), or a previously diagnosed (congenital or acquired) immunodeficiency disorder (including HIV);
  5. Current (or within the 90 days prior to receiving the Study Vaccine) treatment with immunosuppressive or immunomodulative medication, including systemic corticosteroids, as follows:

    •Chronic or long term corticosteroids: >0.5mg/kg/day of oral prednisolone or equivalent (Note: Use of topical or inhalant corticosteroids prior to administration of the Study Vaccine or throughout the Study is acceptable).

  6. Administration of immunoglobulins and/or any blood products since birth or planned administration of such blood products during the study period;
  7. Participation in a clinical study or use of an investigational compound (ie a new chemical or biological entity not registered for clinical use), within the 90 days prior to receiving the Study Vaccine or be planning to enter such a study during the study period;
  8. Current treatment with cytotoxic drugs or treatment within the 6 months prior to administration of the Study Vaccine;
  9. Have a known history of Guillain-Barré Syndrome;
  10. Have a major congenital defect or serious illness and
  11. Have a history of neurologic disorders or seizures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00700193

Australia, Victoria
Murdoch Childrens Research Institute
Melbourne, Victoria, Australia, 3052
Sponsors and Collaborators
Principal Investigator: Terry M Nolan, Prof Murdoch Childrens Research Institute
  More Information

Responsible Party: Dr Russell Basser, CSL Limited Identifier: NCT00700193     History of Changes
Other Study ID Numbers: CSLCT-FLU-04-05
Study First Received: June 17, 2008
Last Updated: July 17, 2016

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017